OncoMatch/Clinical Trials/NCT07281924
Hepzato Kit and Opdualag for Metastatic Melanoma and Liver Metastasis
Is NCT07281924 recruiting? Yes, currently enrolling (Sep 2026). This Phase 1/2 trial studies multiple treatments including Nivolumab and Relatlimab and Melphalan for metastatic melanoma.
Treatment: Nivolumab and Relatlimab · Melphalan — This study is being done to see if combining HEPZATO KIT™ with nivolumab and relatlimab (Opdualag™) in patients with metastatic melanoma with liver metastasis is safe, tolerable, and will have a synergistic effect leading to improved clinical outcomes compared to the historic cohort of patients with liver metastasis treated with combination immune checkpoint inhibitor therapy.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Immunotherapy
Chemotherapy
Cancer type
Melanoma
Disease stage
Metastatic disease required
Prior therapy
Cannot have received: melphalan percutaneous hepatic perfusion (HEPZATO KIT)
Prior treatment with HEPZATO KIT™
Cannot have received: anti-PD-1/PD-L1 and LAG-3 inhibitor combination (nivolumab, relatlimab)
Prior treatment with ... nivolumab and relatlimab (Opdualag™)
Lab requirements
Blood counts
Kidney function
Liver function
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- UW Hospital and Clinics · Madison, Wisconsin
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT07281924 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior melphalan percutaneous hepatic perfusion (HEPZATO KIT), anti-PD-1/PD-L1 and LAG-3 inhibitor combination disqualifies patients from enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages